Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients
NCT ID: NCT04530617
Last Updated: 2021-06-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE2
Total Enrollment
246 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-10-05
Study Completion Date
2021-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a randomized, double-blind, placebo-controlled, multi-arm, multicenter, phase II trial design to allow a rapid efficacy and toxicity assessment of potential therapies (camostat mesilate and artemisia annua) immediately after COVID-19 positive testing in mild to moderate disease and high-risk factors such as diabetes, hypertension, and obesity among others.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
NCT04524663
Covid19
COMPLETED
PHASE2
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
NCT04622865
SARS-CoV 2
COVID-19
Coronavirus Disease 2019
UNKNOWN
PHASE2
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
NCT04486313
COVID-19
COMPLETED
PHASE3
Ivermectin Reproposing for Mild Stage COVID-19 Outpatients
NCT04784481
Covid19
SARS (Severe Acute Respiratory Syndrome)
COMPLETED
PHASE1/PHASE2
Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19
NCT04338906
COVID
WITHDRAWN
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Coronavirus Disease 2019 (COVID-19) is a highly contagious disease, caused by a novel enveloped RNA beta-coronavirus, also known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This disease has caused a global health crisis.
While the majority of patients with COVID-19 develop a mild or uncomplicated illness, approximately 20-30% of hospitalized patients have required intensive care support and 5% of those have multi-organ failure or shock. The case fatality rate ranges from 1 to 4% and it is higher among those with pre-existing comorbid conditions (high-risk) such as cardiovascular disease, diabetes mellitus, obesity, chronic respiratory disease, hypertension, and cancer.
To date, treatments for COVID-19 in high-risk individuals remain experimental and therapeutic strategies to deal with the infection are at best supportive, with prevention aimed at reducing transmission in the community as the best weapon. No proven therapies have been demonstrated to prevent progression of COVID-19 to severe illness in confirmed outpatients with COVID-19 and this is a critical unmet need for high-risk individuals and warrants study. Furthermore, there are no effective medications for the use in outpatients with confirmed mild to moderate COVID-19 disease.
This is a randomized, double-blind, placebo-controlled, multi-arm, multicenter, phase II trial design to allow a rapid efficacy and toxicity assessment of potential therapies, camostat mesilate (serine protease inhibitor) and Artemisia annua (unknown mechanism) immediately after COVID-19 positive testing in mild to moderate disease and high-risk factors such as diabetes, hypertension, and obesity among others. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus, such as Artemisia annua and camostat, will reduce the rate of a composite outcome of hospitalization due to COVID-19 pneumonia or the use of oxygen therapy; will be devoid of additional moderate to severe toxicities; and will improve viral clearance at Day 14 in high-risk individuals. The main hypothesis is that the clinical outcomes in COVID-19 infected patients at higher risk of poor outcomes following infection will be improved compared to the standard of care when introduced as an early intervention after diagnosis.
While the majority of patients with COVID-19 develop a mild or uncomplicated illness, approximately 20-30% of hospitalized patients have required intensive care support and 5% of those have multi-organ failure or shock. The case fatality rate ranges from 1 to 4% and it is higher among those with pre-existing comorbid conditions (high-risk) such as cardiovascular disease, diabetes mellitus, obesity, chronic respiratory disease, hypertension, and cancer.
To date, treatments for COVID-19 in high-risk individuals remain experimental and therapeutic strategies to deal with the infection are at best supportive, with prevention aimed at reducing transmission in the community as the best weapon. No proven therapies have been demonstrated to prevent progression of COVID-19 to severe illness in confirmed outpatients with COVID-19 and this is a critical unmet need for high-risk individuals and warrants study. Furthermore, there are no effective medications for the use in outpatients with confirmed mild to moderate COVID-19 disease.
This is a randomized, double-blind, placebo-controlled, multi-arm, multicenter, phase II trial design to allow a rapid efficacy and toxicity assessment of potential therapies, camostat mesilate (serine protease inhibitor) and Artemisia annua (unknown mechanism) immediately after COVID-19 positive testing in mild to moderate disease and high-risk factors such as diabetes, hypertension, and obesity among others. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus, such as Artemisia annua and camostat, will reduce the rate of a composite outcome of hospitalization due to COVID-19 pneumonia or the use of oxygen therapy; will be devoid of additional moderate to severe toxicities; and will improve viral clearance at Day 14 in high-risk individuals. The main hypothesis is that the clinical outcomes in COVID-19 infected patients at higher risk of poor outcomes following infection will be improved compared to the standard of care when introduced as an early intervention after diagnosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Covid19
Diabetes
Hypertension
Obesity
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
A randomized, placebo-controlled, parallel, multicenter, multi-arm, phase II trial of novel agents for treatment of high-risk COVID-19 positive outpatients. Subjects who meet the inclusion/exclusion criteria and have properly signed the informed consent will be randomized to the test group or placebo group in the ratio of 1:1:1:1.
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
The masking of the protocol will be maintained throughout the duration of the study. This will be done with the use of a matched placebo and a non-continuous coding (tablets in the case of camostat and tea bags/coffer for Artemisia) that has the same description and dose as the interventions so that both, the investigators and the patient does not know the treatment assignment.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Camostat mesilate
100 mg tablet, 600 mg/day. Oral, 2 tablets three times a day, after a meal (600 mg total daily dose) Days 1-14.
Group Type
ACTIVE_COMPARATOR
Camostat Mesilate
Intervention Type
DRUG
Tablets
Camostat Placebo
Matched placebo
Group Type
PLACEBO_COMPARATOR
Camostat Mesilate
Intervention Type
DRUG
Tablets
Artemisia annua
Tea 225mg per bag,1350 mg/day. Oral, one 8 oz brewed tea (two bags) three times a day, Days 1-14.
Group Type
ACTIVE_COMPARATOR
Artemisia Annua Leaf
Intervention Type
DRUG
Tea bags
Artemisia annua Placebo
Matched placebo
Group Type
PLACEBO_COMPARATOR
Artemisia Annua Leaf
Intervention Type
DRUG
Tea bags
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Camostat Mesilate
Tablets
Intervention Type
DRUG
Artemisia Annua Leaf
Tea bags
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Camostat
Artemisia annua
Artemisia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years
* Laboratory-confirmed SARS-CoV-2 infection within 3 days (of proposed consent) or the presence of symptoms or signs providing a high probability of COVID-19 disease who have symptoms within 7 days prior to diagnosis as determined by Infectious Disease specialist or treating physicians.
* Outpatients. No previous hospitalization within the past 3 months.
* Subjects must have at least one of the following high-risk features for clinical deterioration:
* Hypertension
* Diabetes mellitus
* Moderate to severe Chronic Obstructive Pulmonary Disease or asthma
* Cancer patients who have received any immunosuppressive drugs within a year from enrollment.
* Obesity as defined by a body mass index \> 30 kg/m2.
* Living in a nursing home or long-term facility
* Underlying serious heart condition as determined by the treating physician
* Immunocompromised subject as defined by the treating physician or by the Infectious Disease specialist
* Ability to provide informed consent by the patient or healthcare proxy.
* Ability to return for repeated testing and observation to the hospital.
* Patients must have adequate organ and marrow function measured within the last 30 days as defined below:
* platelets ≥100,000
* aspartate transaminase or alanine transaminase ≤3 times institutional upper limit of normal
* creatinine ≤ 1.5 times institutional upper limit of normal OR
* glomerular filtration rate ≥45 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2
* Laboratory-confirmed SARS-CoV-2 infection within 3 days (of proposed consent) or the presence of symptoms or signs providing a high probability of COVID-19 disease who have symptoms within 7 days prior to diagnosis as determined by Infectious Disease specialist or treating physicians.
* Outpatients. No previous hospitalization within the past 3 months.
* Subjects must have at least one of the following high-risk features for clinical deterioration:
* Hypertension
* Diabetes mellitus
* Moderate to severe Chronic Obstructive Pulmonary Disease or asthma
* Cancer patients who have received any immunosuppressive drugs within a year from enrollment.
* Obesity as defined by a body mass index \> 30 kg/m2.
* Living in a nursing home or long-term facility
* Underlying serious heart condition as determined by the treating physician
* Immunocompromised subject as defined by the treating physician or by the Infectious Disease specialist
* Ability to provide informed consent by the patient or healthcare proxy.
* Ability to return for repeated testing and observation to the hospital.
* Patients must have adequate organ and marrow function measured within the last 30 days as defined below:
* platelets ≥100,000
* aspartate transaminase or alanine transaminase ≤3 times institutional upper limit of normal
* creatinine ≤ 1.5 times institutional upper limit of normal OR
* glomerular filtration rate ≥45 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2
Exclusion Criteria
* Severe COVID-19 is defined by one or more of the following:
* blood oxygen saturation ≤ 90%
* partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300
* lung infiltrates ≥ 50% within 24 to 48 hours
* Life-threatening COVID-19 is defined as one or more of the following:
* respiratory failure
* septic shock
* multiple organ dysfunction or failure
* Weight less than 45 kg.
* Pregnant or breast-feeding females
* Subjects on dialysis or with creatinine clearance \< 45 ml/min
* Subjects who need antiviral administration due to severe viral diseases other than COVID-19, such as HIV, hepatitis B, and hepatitis C
* Existing Division of Microbiology and Infectious Disease Toxicity Scale for determining the severity of adverse events grade 3 or greater.
* Uncontrolled seizure disorder
* Subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery.
* Patients with reflux esophagitis after surgery.
* Known allergy to Artemisia annua or camostat mesilate.
* Currently receiving any study medications for other indications.
* Concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication.
Specifically:
* Patients receiving Artemisia annua tea may not be currently taking strong inducers of CYP2A6, including phenobarbital and rifampin.
* Receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol.
* Cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment.
* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
* Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening
* Enrollment on other experimental therapies for COVID-19.
* Inability to receive enteral medications
* Patients with psychiatric illness/social situations that would limit compliance with study requirements.
* Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening
* Any other condition that in the opinion of the treating physician justifies exclusion from the study.
* blood oxygen saturation ≤ 90%
* partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300
* lung infiltrates ≥ 50% within 24 to 48 hours
* Life-threatening COVID-19 is defined as one or more of the following:
* respiratory failure
* septic shock
* multiple organ dysfunction or failure
* Weight less than 45 kg.
* Pregnant or breast-feeding females
* Subjects on dialysis or with creatinine clearance \< 45 ml/min
* Subjects who need antiviral administration due to severe viral diseases other than COVID-19, such as HIV, hepatitis B, and hepatitis C
* Existing Division of Microbiology and Infectious Disease Toxicity Scale for determining the severity of adverse events grade 3 or greater.
* Uncontrolled seizure disorder
* Subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery.
* Patients with reflux esophagitis after surgery.
* Known allergy to Artemisia annua or camostat mesilate.
* Currently receiving any study medications for other indications.
* Concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication.
Specifically:
* Patients receiving Artemisia annua tea may not be currently taking strong inducers of CYP2A6, including phenobarbital and rifampin.
* Receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol.
* Cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment.
* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
* Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening
* Enrollment on other experimental therapies for COVID-19.
* Inability to receive enteral medications
* Patients with psychiatric illness/social situations that would limit compliance with study requirements.
* Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening
* Any other condition that in the opinion of the treating physician justifies exclusion from the study.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose G Gotes Palazuelos, MD
Role: PRINCIPAL_INVESTIGATOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, None - Non-US/Canada, Mexico
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Mexico
References
Explore related publications, articles, or registry entries linked to this study.
Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3. No abstract available.
Reference Type
BACKGROUND
Del Rio C, Malani PN. COVID-19-New Insights on a Rapidly Changing Epidemic. JAMA. 2020 Apr 14;323(14):1339-1340. doi: 10.1001/jama.2020.3072. No abstract available.
Reference Type
RESULT
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Reference Type
RESULT
Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020 Apr;76:71-76. doi: 10.1016/j.ijsu.2020.02.034. Epub 2020 Feb 26.
Reference Type
RESULT
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
Reference Type
RESULT
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
Reference Type
RESULT
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
Reference Type
RESULT
Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb 19;368:m606. doi: 10.1136/bmj.m606.
Reference Type
RESULT
Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, Antinori S, Galli M. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin Infect Dis. 2020 Jul 28;71(15):889-890. doi: 10.1093/cid/ciaa330. No abstract available.
Reference Type
RESULT
Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B, Yousey-Hindes K, Niccolai L, Anderson EJ, Openo KP, Weigel A, Monroe ML, Ryan P, Henderson J, Kim S, Como-Sabetti K, Lynfield R, Sosin D, Torres S, Muse A, Bennett NM, Billing L, Sutton M, West N, Schaffner W, Talbot HK, Aquino C, George A, Budd A, Brammer L, Langley G, Hall AJ, Fry A. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464. doi: 10.15585/mmwr.mm6915e3.
Reference Type
RESULT
Ortiz-Brizuela E, Villanueva-Reza M, Gonzalez-Lara MF, Tamez-Torres KM, Roman-Montes CM, Diaz-Mejia BA, Perez-Garcia E, Olivas-Martinez A, Rajme-Lopez S, Martinez-Guerra BA, de-Leon-Cividanes NA, Fernandez-Garcia OA, Guerrero-Torres L, Torres-Gonzalez L, Carrera-Patino FA, Corral-Herrera EA, Hernandez-Alemon AN, Tovar-Vargas MLA, Serrano-Pinto YG, Espejo-Ortiz CE, Morales-Ortega ML, Lozano-Cruz OA, Cardenas-Fragoso JL, Vidal-Mayo JJ, Hernandez-Gilsoul T, Rivero-Sigarroa E, Dominguez-Cherit G, Cervantes-Villar LE, Ramos-Cervantes MDP, Ibarra-Gonzalez V, Calva-Mercado JJ, Sierra-Madero JG, Lopez-Iniguez A, Ochoa-Hein E, Crabtree-Ramirez BE, Galindo-Fraga A, Guerrero-Almeida ML, Ruiz-Palacios GM, Gulias-Herrero A, Sifuentes-Osornio J, Kershenobich-Stalnikowitz D, Ponce-de-Leon A. CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS DIAGNOSED WITH COVID-19 IN A TERTIARY CARE CENTER IN MEXICO CITY: A PROSPECTIVE COHORT STUDY. Rev Invest Clin. 2020;72(3):165-177. doi: 10.24875/RIC.20000211.
Reference Type
RESULT
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O'Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020 Apr 27:ciaa478. doi: 10.1093/cid/ciaa478. Online ahead of print.
Reference Type
RESULT
Yamaya M, Shimotai Y, Hatachi Y, Lusamba Kalonji N, Tando Y, Kitajima Y, Matsuo K, Kubo H, Nagatomi R, Hongo S, Homma M, Nishimura H. The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells. Pulm Pharmacol Ther. 2015 Aug;33:66-74. doi: 10.1016/j.pupt.2015.07.001. Epub 2015 Jul 10.
Reference Type
RESULT
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
Reference Type
RESULT
Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012 Jun;86(12):6537-45. doi: 10.1128/JVI.00094-12. Epub 2012 Apr 11.
Reference Type
RESULT
Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Pohlmann S, McKerrow JH, Renslo AR, Simmons G. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015 Apr;116:76-84. doi: 10.1016/j.antiviral.2015.01.011. Epub 2015 Feb 7.
Reference Type
RESULT
Coote K, Atherton-Watson HC, Sugar R, Young A, MacKenzie-Beevor A, Gosling M, Bhalay G, Bloomfield G, Dunstan A, Bridges RJ, Sabater JR, Abraham WM, Tully D, Pacoma R, Schumacher A, Harris J, Danahay H. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther. 2009 May;329(2):764-74. doi: 10.1124/jpet.108.148155. Epub 2009 Feb 3.
Reference Type
RESULT
Rowe SM, Reeves G, Hathorne H, Solomon GM, Abbi S, Renard D, Lock R, Zhou P, Danahay H, Clancy JP, Waltz DA. Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis. Chest. 2013 Jul;144(1):200-207. doi: 10.1378/chest.12-2431.
Reference Type
RESULT
Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci. 2008 Oct;29(10):520-7. doi: 10.1016/j.tips.2008.07.004. Epub 2008 Aug 25.
Reference Type
RESULT
Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med. 2008 Apr 24;358(17):1829-36. doi: 10.1056/NEJMct0709050. No abstract available.
Reference Type
RESULT
Zhang X, Zhao Y, Guo L, Qiu Z, Huang L, Qu X. Differences in chemical constituents of Artemisia annua L from different geographical regions in China. PLoS One. 2017 Sep 7;12(9):e0183047. doi: 10.1371/journal.pone.0183047. eCollection 2017.
Reference Type
RESULT
Munyangi J, Cornet-Vernet L, Idumbo M, Lu C, Lutgen P, Perronne C, Ngombe N, Bianga J, Mupenda B, Lalukala P, Mergeai G, Mumba D, Towler M, Weathers P. Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial. Phytomedicine. 2019 Apr;57:49-56. doi: 10.1016/j.phymed.2018.12.002. Epub 2018 Dec 5.
Reference Type
RESULT
Naesens L, Bonnafous P, Agut H, De Clercq E. Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. J Clin Virol. 2006 Dec;37 Suppl 1:S69-75. doi: 10.1016/S1386-6532(06)70015-4.
Reference Type
RESULT
Li SY, Chen C, Zhang HQ, Guo HY, Wang H, Wang L, Zhang X, Hua SN, Yu J, Xiao PG, Li RS, Tan X. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res. 2005 Jul;67(1):18-23. doi: 10.1016/j.antiviral.2005.02.007.
Reference Type
RESULT
Wang C, Xuan X, Yao W, Huang G, Jin J. Anti-profibrotic effects of artesunate on bleomycin-induced pulmonary fibrosis in Sprague Dawley rats. Mol Med Rep. 2015 Jul;12(1):1291-7. doi: 10.3892/mmr.2015.3500. Epub 2015 Mar 17.
Reference Type
RESULT
Berry SM, Alarid ET, Beebe DJ. One-step purification of nucleic acid for gene expression analysis via Immiscible Filtration Assisted by Surface Tension (IFAST). Lab Chip. 2011 May 21;11(10):1747-53. doi: 10.1039/c1lc00004g. Epub 2011 Mar 21.
Reference Type
RESULT
Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004 Apr;136(1):95-103. doi: 10.1111/j.1365-2249.2004.02415.x.
Reference Type
RESULT
Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018 Apr;104:8-13. doi: 10.1016/j.cyto.2018.01.025. Epub 2018 Feb 2.
Reference Type
RESULT
Gee JR, Saltzstein DR, Kim K, Kolesar J, Huang W, Havighurst TC, Wollmer BW, Stublaski J, Downs T, Mukhtar H, House MG, Parnes HL, Bailey HH. A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers. Cancer Prev Res (Phila). 2017 May;10(5):298-307. doi: 10.1158/1940-6207.CAPR-16-0167. Epub 2017 Mar 21.
Reference Type
RESULT
Related Links
Access external resources that provide additional context or updates about the study.
http://coronavirus.jhu.edu/map.html
ohns Hopkins University of Medicine Coronavirus Resource Center Map
http://www.afro.who.int/news/who-supports-scientifically-proven-traditional-medicine?gclid=Cj0KCQjwl4v4BRDaARIsAFjATPl33iRfzJnqBsVQDc6PIIoDX-getuaRtwPYEEGF_Suop-Y1tbPr7dAaAkNYEALw_wcB
WHO supports scientifically-proven traditional medicine.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3421
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C
NCT00890318
COMPLETED
PHASE1
Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms
NCT05795816
COMPLETED
PHASE3
Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection
NCT03196921
WITHDRAWN
PHASE1/PHASE2
The Effects of Repeated Exposure to Antiseptics During COVID-19 Pandemic on Skin Parameters
NCT05276102
UNKNOWN
NA
A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis
NCT05089409
COMPLETED
PHASE1
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.
NCT05770466
COMPLETED
PHASE3
QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo
NCT01191723
COMPLETED
PHASE1
Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation
NCT06795165
COMPLETED
PHASE4
Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization
NCT01565720
COMPLETED
PHASE1
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
NCT00535470
COMPLETED
PHASE2
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
NCT03346837
COMPLETED
PHASE1
A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants
NCT01929876
COMPLETED
PHASE1
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
NCT01397461
COMPLETED
PHASE3
IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study
NCT01549106
COMPLETED
PHASE1
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333
NCT00768690
COMPLETED
PHASE1
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
NCT00168064
COMPLETED
PHASE2
Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design
NCT06369727
COMPLETED
PHASE1
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
NCT07018635
COMPLETED
PHASE1
Calcifediol in the Treatment of COVID 19
NCT05819918
COMPLETED
Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo
NCT01013909
COMPLETED
PHASE2
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
NCT04335071
TERMINATED
PHASE2
A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults
NCT05064449
COMPLETED
PHASE1
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
NCT07160738
RECRUITING
PHASE1
Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects
NCT01473069
TERMINATED
PHASE1
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
NCT04472585
UNKNOWN
PHASE1/PHASE2